Table 4.
Family cardiovascular risk and lipid status biomarkers of CVID patients and control group
| Variables | CVID Patients (n = 32) |
Control group (n = 37) |
p* |
|---|---|---|---|
| Median (IQ25–75) | Median (IQ25–75) | ||
| Family CVR Yes | 13 (40.6) | 16 (43.2) | 0.826 |
| Lipid status biomarkers | |||
| Total cholesterol mg/dL | 166.0 (138.5–185.0) | 179.0 (164.0–213.0) | 0.085 |
| LDL-c mg/dL | 100.1 (86.0–116.6) | 108.8 (84.2–139.0) | 0.237 |
| Triglycerides mg/dL | 91.0 (78.5–104.0) | 91.0 (75.0–121.0) | 0.995 |
| HDL-c mg/dL | 43.0 (34.5–52.5) | 48.0 (37.0–56.0) | 0.210 |
| NHDL-c mg/dL, % | 118.0 (104.0–138.0) | 135.0 (108.0–161.0) | 0.226 |
| VLDL-c mg/dL | 18.2 (15.6–20.8) | 18.2 (15.0–24.2) | 0.990 |
| Remnant cholesterol mg/dL | 18.5 (15.6–20.8) | 18.2 (15.0–22.8) | 0.909 |
| Oxidized LDL mg/dL | 45.3 (26.8–65.7) | 33.3 (23.7–42.2) | 0.016 |
| Apo A-1 mg/dL | 98.5 (81.5–112.5) | 117.0 (92.0–130.0) | 0.008 |
| Apo B mg/dL | 94.0 (81.0–111.5) | 102.0 (90.0–119.0) | 0.215 |
| Apo B/ Apo A-1 | 0.9 (0.7–1.1) | 0.8 (0.6–1.0) | 0.238 |
| Total cholesterol/HDL-c | 4.0 (3.0–4.0) | 4.0 (3.0–4.0) | 0.484 |
| LDL-c/ Apo B | 1.0 (0.9–1.2) | 1.0 (0.9–1.2) | 0.976 |
| LDL-c/ HDL-c | 2.0 (2.0–3.0) | 2.0 (2.0–3.0) | 0.442 |
| TG/ HDL-c | 2.0 (2.0–3.0) | 2.0 (1.0–3.0) | 0.516 |
| Apo A-1/ HDL-c | 2.3 (1.9–2.5) | 2.3 (1.2–2.6) | 0.392 |
* Significance level Mann-Whitney test
CVR Cardiovascular risk, LDL-c Low-density lipoprotein, HDL-c High-density lipoprotein, NHDL-c Non-HDL cholesterol, VLDL-c Very low-density lipoprotein, TG Triglycerides, Apo A-1 Apolipoprotein A-1